Roger Dansey, Seagen CEO (via Merck)
As Merck buyout buzz heats up, Seagen touts a positive update on their Padcev/Keytruda combo
Most of the news at Seagen these days revolves around hot buzz about a potential $40 billion-plus Merck buyout. But today the focus has shifted …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
